Filtered By:
Condition: Cold Sores
Vaccination: Hepatitis Vaccine
This page shows you your search results in order of date.
Order by Relevance | Date
Total 55 results found since Jan 2013.
Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panel
Blood Cancer J. 2023 Aug 1;13(1):116. doi: 10.1038/s41408-023-00879-7.ABSTRACTBispecific antibodies (BsAbs) are emerging as an important novel class of immunotherapeutic agents for the treatment of multiple myeloma (MM), and are set to be more widely used in clinical practice. However, this new class of therapies is associated with a distinct adverse event (AE) profile that includes cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome, as well as AEs leading to increased infection risk such as cytopenias and hypogammaglobulinemia, and infections themselves. As preliminary data with this clas...
Source: Herpes - August 1, 2023 Category: Infectious Diseases Authors: Noopur Raje Kenneth Anderson Hermann Einsele Yvonne Efebera Francesca Gay Sarah P Hammond Alexander M Lesokhin Sagar Lonial Heinz Ludwig Philippe Moreau Krina Patel Karthik Ramasamy Maria-Victoria Mateos Source Type: research
Sexual and reproductive health needs of young women living with perinatally acquired HIV
CONCLUSION: High rates of unplanned pregnancy, STIs and cervical abnormalities highlight the continuing SRH needs of YWLPaHIV and requirement for open access to integrated HIV/SRH services despite pandemic restrictions.PMID:37279784 | DOI:10.1177/09564624231179768
Source: Herpes - June 6, 2023 Category: Infectious Diseases Authors: Veronica R Nott George A Hazell Sara Ayres Natalie Kirkhope Sarah Fidler Caroline Foster Source Type: research
Combination Therapy for the Treatment of Shingles with an Immunostimulatory Vaccine Virus and Acyclovir
Pharmaceuticals (Basel). 2023 Feb 1;16(2):226. doi: 10.3390/ph16020226.ABSTRACTPractically the entire global population is infected by herpesviruses that establish lifelong latency and can be reactivated. Alpha-herpesviruses, herpes simplex viruses 1 and 2 (HSV-1/HSV-2) and varicella zoster virus (VZV), establish latency in sensory neurons and then reactivate to infect epithelial cells in the mucosa or skin, resulting in a vesicular rash. Licensed antivirals inhibit virus replication, but do not affect latency. On reactivation, VZV causes herpes zoster, also known as shingles. The 76-year-old first author of this paper pub...
Source: Herpes - June 1, 2023 Category: Infectious Diseases Authors: Tibor Bakacs Volker Sandig Imre Kovesdi Source Type: research
Human inherited complete STAT2 deficiency underlies inflammatory viral diseases
We report 23 patients with loss of function variants causing autosomal recessive (AR), complete STAT2 deficiency. Both cells transfected with mutant STAT2 alleles and the patients' cells display impaired expression of interferon stimulated genes and impaired control of in-vitro viral infections. Clinical manifestations from early childhood onward include severe adverse reaction to live attenuated viral vaccines (LAV, 12/17 patients) and severe viral infections (10/23 patients), particularly critical influenza pneumonia (6 patients), critical COVID-19 pneumonia (1 patient), and herpes simplex encephalitis (1 patient). The p...
Source: Herpes - March 28, 2023 Category: Infectious Diseases Authors: Giorgia Bucciol Leen Moens Masato Ogishi Darawan Rinchai Daniela Matuozzo Mana Momenilandi Nacim Kerrouche Catherine M Cale Elsa R Treffeisen Mohammad Al Salamah Bandar K Al-Saud Alain Lachaux Remi Duclaux-Loras Marie Meignien Aziz Bousfiha Ibtihal Benhsa Source Type: research
Risk of infections in patients with pemphigus treated with rituximab versus azathioprine or mycophenolate mofetil: A large-scale global cohort study
CONCLUSION: Within the first 12 months after treatment, patients under rituximab experience an elevated risk of COVID-19, parasitic and CMV infections. Rituximab is associated with pneumonia, osteomyelitis, and viral diseases even beyond the first year after therapy. Pneumococcal vaccine and suppressive antiviral therapy should be considered even one year following therapy. No signal for elevated risk of tuberculosis, hepatitis B virus reactivation, pneumocystis jiroveci pneumonia, and progressive multifocal leukoencephalopathy.PMID:36763798 | DOI:10.1093/bjd/ljac118
Source: The British Journal of Dermatology - February 10, 2023 Category: Dermatology Authors: Khalaf Kridin Noor Mruwat Kyle T Amber Ralf J Ludwig Source Type: research
Application of Cell Penetrating Peptides as a Promising Drug Carrier to Combat Viral Infections
Mol Biotechnol. 2023 Jan 31. doi: 10.1007/s12033-023-00679-1. Online ahead of print.ABSTRACTNovel effective drugs or therapeutic vaccines have been already developed to eradicate viral infections. Some non-viral carriers have been used for effective drug delivery to a target cell or tissue. Among them, cell penetrating peptides (CPPs) attracted a special interest to enhance drug delivery into the cells with low toxicity. They were also applied to transfer peptide/protein-based and nucleic acids-based therapeutic vaccines against viral infections. CPPs-conjugated drugs or vaccines were investigated in several viral infectio...
Source: Herpes - January 31, 2023 Category: Infectious Diseases Authors: Niloofar Khairkhah Ali Namvar Azam Bolhassani Source Type: research
Virus-CKB 2.0: Viral-Associated Disease-Specific Chemogenomics Knowledgebase
ACS Omega. 2022 Oct 10;7(42):37476-37484. doi: 10.1021/acsomega.2c04258. eCollection 2022 Oct 25.ABSTRACTTransmissible and infectious viruses can cause large-scale epidemics around the world. This is because the virus can constantly mutate and produce different variants and subvariants to counter existing treatments. Therefore, a variety of treatments are urgently needed to keep up with the mutation of the viruses. To facilitate the research of such treatment, we updated our Virus-CKB 1.0 to Virus-CKB 2.0, which contains 10 kinds of viruses, including enterovirus, dengue virus, hepatitis C virus, Zika virus, herpes simplex...
Source: Herpes - October 31, 2022 Category: Infectious Diseases Authors: Yixuan Hao Maozi Chen Yasmin Othman Xiang-Qun Xie Zhiwei Feng Source Type: research
Results of Novel Clinical Study of Guselkumab and Golimumab Combination Therapy Show Adults with Moderately to Severely Active Ulcerative Colitis Maintained Higher Rates of Clinical, Histologic, and Endoscopic Remission at Week 38
SPRING HOUSE, PENNSYLVANIA, October 10, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from an ongoing analysis of a Phase 2a clinical trial showing adults with moderately to severely active ulcerative colitis (UC) who received 12 weeks of combination induction therapy with guselkumab and golimumab, followed by a transition to guselkumab alone for maintenance, achieved a clinical remission ratea (based on the modified Mayo score [mMayo])b at week 38 of 47.9 percent, a higher rate than induction and maintenance treatment with either guselkumab alone (31.0 percent) or golimumab al...
Source: Johnson and Johnson - October 10, 2022 Category: Pharmaceuticals Source Type: news
